Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition

作者：Qi Wang, Juan Liu, Yinan Hu, Ting Pan, Yongjian Xu, Jun Yu, Weining Xiong, Qing Zhou, Yi Wang · 发表于：Theranostics · 年份：2021 · DOI：10.7150/thno.61085 · 被引用次数：72 · 研究领域：Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis、Medical Imaging and Pathology Studies、Neonatal Respiratory Health Research

Accordingly, these data indicate that Srpx2 plays an essential role in the pathogenesis of pulmonary fibrosis and suggests the strategy aiming at silencing Srpx2 could be a promising therapeutic approach against pulmonary fibrosis in clinical settings.